Biogened (WAR:BGD) Cyclically Adjusted Revenue per Share: zł35.52 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:BGD Biogened SA WAR:BGD
75 GF Score
Price zł21.80
GF Value zł24.01
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Biogened Cyclically Adjusted Revenue per Share?

Biogened WAR:BGD 75 Cyclically Adjusted Revenue per Share is zł35.52 as of Jun. 2026. GuruFocus rates WAR:BGD with a GF Score™ of 75/100 and a GF Value™ of zł24.01 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biogened's adjusted revenue per share for the three months ended in Jun. 2026 was zł12.543. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is zł35.52 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Biogened's average Cyclically Adjusted Revenue Growth Rate was 9.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biogened was 14.90% per year. The lowest was 11.60% per year. And the median was 13.25% per year.

As of today (2026-09-15), Biogened's current stock price is zł21.80. Biogened's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was zł35.52. Biogened's Cyclically Adjusted PS Ratio of today is 0.61.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biogened was 1.14. The lowest was 0.37. And the median was 0.62.


Biogened  (WAR:BGD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biogened's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=21.80/35.52
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biogened was 1.14. The lowest was 0.37. And the median was 0.62.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biogened Cyclically Adjusted Revenue per Share Related Terms


Biogened Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Biogened's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogened Cyclically Adjusted Revenue per Share Chart

Biogened Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.18 24.03 27.12 30.61 33.44

Biogened Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.47 32.89 33.44 35.04 35.52

WAR:BGD vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biogened's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogened Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogened's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biogened's Cyclically Adjusted PS Ratio falls into.


WAR:BGD
75GF Score
Biogened SA WAR:BGD
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogened Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogened's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=12.543/162.2800*162.2800
=12.543

Current CPI (Jun. 2026) = 162.2800.

Biogened Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 3.629 99.064 5.945
201612 1.938 100.366 3.134
201703 3.434 101.018 5.517
201706 4.018 101.180 6.444
201709 2.962 101.343 4.743
201712 3.257 102.564 5.153
201803 4.562 102.564 7.218
201806 4.917 103.378 7.719
201809 3.061 103.378 4.805
201812 3.845 103.785 6.012
201903 4.921 104.274 7.659
201906 5.925 105.983 9.072
201909 3.742 105.983 5.730
201912 4.400 107.123 6.666
202003 5.601 109.076 8.333
202006 5.730 109.402 8.500
202009 4.099 109.320 6.085
202012 4.249 109.565 6.293
202103 6.099 112.658 8.785
202106 7.453 113.960 10.613
202109 5.474 115.588 7.685
202112 7.572 119.088 10.318
202203 8.160 125.031 10.591
202206 8.190 131.705 10.091
202209 7.316 135.531 8.760
202212 8.752 139.113 10.210
202303 10.400 145.950 11.564
202306 9.993 147.009 11.031
202309 8.113 146.113 9.011
202312 10.402 147.741 11.426
202403 12.048 149.044 13.118
202406 12.500 150.997 13.434
202409 8.705 153.439 9.207
202412 11.914 154.660 12.501
202503 13.376 157.021 13.824
202506 11.913 157.509 12.274
202509 9.669 158.000 9.931
202512 11.477 158.320 11.764
202603 11.524 163.070 11.468
202606 12.543 162.280 12.543

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of zł35.52 mean?
Biogened (WAR:BGD) has a Cyclically Adjusted Revenue per Share of zł35.52 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biogened and its competitors.
Is Biogened's Cyclically Adjusted Revenue per Share too high?
Biogened's current Cyclically Adjusted Revenue per Share is zł35.52. Overall, Biogened has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biogened's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Biogened's Cyclically Adjusted Revenue per Share of zł35.52 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biogened and its competitors. Biogened's current Cyclically Adjusted Revenue per Share is zł35.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogened stock overvalued right now?
Based on GuruFocus' analysis, Biogened (WAR:BGD) is currently considered Fairly Valued. The stock's GF Value™ is zł24.01, compared to a current price of zł21.80 — trading 9.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is zł35.52. Biogened's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Biogened (WAR:BGD), the current Cyclically Adjusted Revenue per Share is zł35.52 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogened (WAR:BGD) Overvalued in 2026?

Based on GuruFocus' analysis, Biogened stock appears to be undervalued. The current stock price of zł21.80 is trading 9.2% below its estimated GF Value™ of zł24.01. GuruFocus considers Biogened to be Fairly Valued.

Key valuation signals for WAR:BGD:

  • Cyclically Adjusted Revenue per Share: zł35.52
  • GF Value™: zł24.01 vs. price of zł21.80 (9.2% below fair value)
  • GF Score™: 75/100 with 4 warning signs

No single metric tells the full story. See the WAR:BGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogened Business Description

Address Ulica Pojezierska 99, Lodz, POL, 91-342
Biogened SA is involved in manufacturing cosmetic and hygiene products. It also designs, produces, and markets safe, effective dermo-cosmetics under the Dermedic brand. The company's products include Dermocosmetics, Thermal water, and Pharmaceutical manufacturing conditions.
75GF Score

Get the complete analysis for WAR:BGD

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł21.80
Price
zł24.01
GF Value